New Protein based treatment of COVID - 19 reduces the symptoms of Virus effect...

Protein based COVID 19 treatment

The new treatment of corona virus could significantly reduce the death from the disease according to the trial results. It uses the protein which helps to the body produce the defense against the virus.

This treatment developed by Southampton based biotech Syniargen (UK) which is the largest drug discovery and drug development company founded by the university of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic.

So how does it actually works ?

The protein interferon beta is part of the bodies first line of defense against the viruses warning it to expect the viral attack. The coronary virus seems to suppress its production as part of its strategy to evade our immune system. The new drug is a special formulation of interferon beta delivered directly the airways through the nebulizer well the trial of the drug has been small scale so far but with promising results.

The researchers said "the initial results of this clinical trial are very encouraging they suggest the patients are 80 % less likely to deteriorate once they were in hospital and the patients could fully recovered within a month and they are suffer less breathlessness which is the one of the key symptoms in COVID 19 and they also spend less time in hospital on average and would discharge three days earlier six days instead of nine days

Working in trial

The Clinical researchers take all the evidence they have got all the data they have collected in this trial and they are striclty test it and they would look into the presentation of this strategy to the regulatory bodies in the United Kingdom and also in the USA FDA( Food and Drugs Administration) and the European Medicinal Agency in Europe and elsewhere in the world.

Interesting think: its done through a nebulizer !

This protein delivered directly into the lung as they said the protein kind of improves the bodies immune response so what is really doing is getting into our own body to attempt to overcome the virus and what they thought that, this treatment would be best in people who would only caught the virus whose body does not been overwhelmed the virus and whats actually surprising about the results of this treatment , is that it worked so well or it appears to work so well in patients with COVID 19 or the patients would appears very quite developing the disease.

If you look at the recent drugs that have been suggested that a promising activity REMDESIVIR produced by the American company Gilead or Dexamethazone which is a steroid which appears to only works in certain cohort of patients but this protein based treatment ( interferon beta ) delivers directly into the lungs through a nebulizer will works whole spectrum of patients

Coming next

The Synairgen chief executive Richard Marsden told that the company will be presenting its findings to the international medical regulators over the coming days. Following this they will get the approval for the treatment. If any circumstances they are not granted emergency approval , as was the case with Remdesivir , this process could take several months.

If it receive approval soon , both the treatment and nebulizer are comes in administration so that it will need to manufacture in large quantities.